Long-term natalizumab treatment enhances the pathogenic signature of Th17 cells - potential implications for treatment cessation?

Janoschka C, Schulte-Mecklenbeck A, Starost L, Schafflick D, Schneider-Hohendorf T, Hoerste GM, Gross CC, Schwab N, Kuhlmann T, Wiendl H, Klotz L

Research article (journal) | Peer reviewed

Details about the publication

Journal: Multiple Sclerosis (Mult Scler)

Volume: 24

Issue: 2

Page range: 669-670

Status: Published

Release year: 2018

Language in which the publication is written: English

Groß, Catharina	Department for Neurology
Janoschka, Claudia	Department for Neurology
Klotz, Luisa Hildegard	Department for Neurology
Meyer zu Hörste, Gerd	Department for Neurology
Schafflick, David	Department for Neurology
Schneider-Hohendorf, Tilman	Department for Neurology
Schulte-Mecklenbeck, Andreas	Department for Neurology
Schwab, Nicholas Christopher	Department for Neurology
Wiendl, Heinz Siegfried	Department for Neurology